)

Codexis (CDXS) investor relations material
Codexis Cantor Global Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Industry context and demand trends
- siRNA therapeutics are gaining momentum, with projected demand rising from 100 kg in 2023 to potentially 50 metric tons or more by decade's end, driven by new entrants and expanding indications. 
- Current chemical synthesis methods for siRNA are inefficient, costly, and limited in scalability, creating a supply bottleneck for future high-volume needs. 
- Enzymatic synthesis is positioned as the only viable solution for meeting large-scale siRNA demand, with industry leaders and new players recognizing this shift. 
- Conferences like Tides have become key venues for showcasing technological advances and generating significant customer interest and leads. 
- The field is transitioning from chemical to chemoenzymatic and fully enzymatic manufacturing, with enzymatic methods enabling new product possibilities. 
Technology and platform offerings
- The company offers a flexible toolbox: ligation (chemoenzymatic), end-to-end enzymatic synthesis, and hybrid approaches tailored to customer needs. 
- Demonstrated ability to synthesize complex drugs like Inclisiran using multiple methods, including full enzymatic and hybrid processes. 
- Recent technical milestones include controlling molecular chirality and scaling up to 10 g, with plans to demonstrate 100 g at upcoming conferences. 
- Internal GMP facility commissioning is a near-term milestone, supporting clinical trial supply and customer confidence. 
- Enzymatic processes offer advantages in purity, scalability, and infrastructure simplicity, reducing costs and setup times compared to chemical methods. 
Customer engagement and business model
- Customer engagement spans from simple supply agreements for ligases to long-term development partnerships for the ECO Synthesis platform. 
- Contract structures vary: large pharma prefers cost-per-run models, while early-stage companies may involve royalties and shared upside. 
- The company is selective, targeting early-phase assets with high potential and credible management, aiming to lock in future revenue streams. 
- Customer conversion rates are high, with a growing pipeline and a focus on building long-term relationships. 
- The business model shifts from modest early-stage economics to significant revenue as drugs advance through clinical development and scale. 
Next Codexis earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
Frequently asked questions
- Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free. 
- Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions. 
- Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more. 
Explore our global coverage
)
)